Overview

This trial is active, not recruiting.

Condition human response to influenza vaccine
Treatment trivalent inactivated influenza vaccine (tiv)
Phase phase 4
Sponsor Stanford University
Collaborator National Institute of Allergy and Infectious Diseases (NIAID)
Start date October 2007
End date January 2015
Trial size 90 participants
Trial identifier NCT01827462, 1U19AI090019-01, 51731, AG-NS-0792-11, SU-03192011-7599

Summary

The immune system is central to human health and its impairment can have serious consequences.

One of the hallmarks of aging is the progressive loss of immune function exposing older people to increased risk from infectious diseases that would not normally be more than an inconvenience. This project will use state-of-the-art technology developed by the Stanford Human Immune Monitoring Center to survey older individuals for signs of immune system aging and to gather information about the factors associated with the decline of immune function.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose prevention
Arm
(Experimental)
trivalent inactivated influenza vaccine (TIV)
trivalent inactivated influenza vaccine (tiv) Fluzone (IM)
Licensed Seasonal Influenza Vaccine

Primary Outcomes

Measure
Abundance levels of cell subsets, serum cytokines, and mRNA transcripts in blood
time frame: Day 0 to Day 28
Single cell phosphoprotein abundance changes in response to immune perturbations
time frame: Day 0 to Day 28
Serum antibody assay: HAI titer
time frame: Day 0 to Day 28

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Prior participant in Years 1, 2, and/or 3 of this study - Age 18-30, 60-79, or 80-100 years, inclusive at time of initial enrollment - General good health and ambulatory at time of enrollment - No acute illness at time of vaccination - Willing and able to sign Informed Consent - Available for follow-up for the planned duration of the study - Acceptable medical history by screening evaluation and brief clinical assessment - All female subjects of childbearing potential must use an acceptable method of contraception and not become pregnant for the duration of the clinical phase of the study (approximately 1 month to completion of Visit 3). (Acceptable contraception may include implants, injectables, combined oral contraceptives, effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner). Exclusion Criteria: - Prior off-study vaccination with TIV or LAIV in the current flu season - Allergy to egg or egg products - Allergy to vaccine components, including thimerosal - Active systemic or serious concurrent illness, including febrile illness on the day of vaccination - History of immunodeficiency - Any chronic disorder which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol. - Blood pressure >150 systolic or > 95 diastolic at Visit 1 - Chronic Hepatitis B or C. - Recent or current use of systemic immunosuppressive medication, including glucocorticoids (corticosteroid nasal sprays and inhaled steroids are permissible). Use of oral steroids (<20mg prednisone-equivalent/day) may be acceptable after review by the investigator. - Autoimmune disease (including rheumatoid arthritis treated with immunosuppressive medication such as Plaquenil, methotrexate, prednisone, Enbrel) which, in the opinion of the investigator, might jeopardize volunteer safety or compliance with the protocol. - History of blood dyscrasias or hemoglobinopathies requiring regular medical follow up or hospitalization during the preceding year - Use of anti-coagulation medication such as Coumadin or Lovenox, or anti-platelet agents such as aspirin, Plavix, Aggrenox must be reviewed by investigator to determine if this would affect the volunteer's safety. - Receipt of blood or blood products within the past 6 months - Medical or psychiatric condition or occupational responsibilities that preclude subject compliance with the protocol - Receipt of inactivated vaccine within 14 days prior to vaccination - Receipt of live, attenuated vaccine within 60 days of vaccination - History of Guillain-Barré Syndrome - Pregnant or lactating woman - Use of investigational agents within 30 days prior to enrollment - Donation of the equivalent of a unit of blood within 6 weeks prior to enrollment - Any condition which, in the opinion of the investigator, might interfere with volunteer safety, study objectives or the ability of the participant to understand or comply with the study protocol.

Additional Information

Official title Immune Senescence in the Elderly: Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages
Principal investigator Cornelia L Dekker, MD
Description At the initial study visit each year, volunteers will provide information about their current health and health history. Vital signs will be assesed and the volunteer will be immunized with the current licensed seasonal influenza vaccine. Follow-up visits will be conducted on Day 6-8 and Day 28, with a phone call at 6 months post-immunization. A blood sample will be collected pre-immunization and at each follow-up visit. Volunteers will be followed for up to 8 years. Our main effort will be to survey elderly and younger control subject responses to influenza vaccination using our functional cellular array technology. We will compare these results with serum antibody responses from day 28 blood samples measuring hemagglutination inhibition (HAI) titers against the vaccination strains. This is the accepted standard for determining whether there is an effective antibody response to influenza vaccine antigens. In addition, we will follow-up subjects yearly by phone to ask whether they have experienced any influenza-like illness episodes or serious adverse events following immunization. In this way, we will be able to correlate the accepted standard assay for an appropriate antibody response to influenza vaccination with our new assay, and also begin what we hope will be a valuable longitudinal study of immune responsiveness in the elderly. We also think that there will be a T-cell array "signature" of immune senescence both in terms of the number of responding cells and their cytokine profile that will both allow a more rapid read-out of this condition (day 6-8 after vaccination) and give some mechanistic clues regarding this phenomenon. In addition, we want to obtain as much information as possible with these samples and thus propose to do the following assays: - Subject Analysis - We will use fluorescence activated cell sorting to determine the precise number of each white blood cell type in a given patient sample and their activation state (B cells, T cells, NK cells, gamma-delta T cells, monocytes, dendritic cells). We are particularly interested in whether the reports of increased CD8+CD28- T cells or decreased gamma-delta T cells correlate with immunosenescence. This subset analysis also will be important for normalizing the gene expression data. - Gene Expression Analysis- We will collect part of the blood sample in a PAX gene tube and prepare probes from the mRNA for gene expression analysis using Agilent microarrays that survey global gene expression. This will tell us if there is a particular "gene expression signature" that correlates with immune senescence. - Serum Cytokine Analysis - As there have been reports of changes in the serum cytokine repertoire in older people, we will survey serum samples for 26 different cytokines using the Panomics/Luminex system now running the Human Immune Monitoring Center at Stanford. - Monocyte Activation Potential - As antigen presentation capacity may also be a variable influencing the robustness of the adaptive immune response, in Year 1 we examined circulating monocytes as a source of antigen presenting cells. We examined the potential of these cells to respond to in vitro activating stimuli ( cytokines and LPS) as measured by expression of cell surface activation markers (DR, CD86, CD40) and intracellular phosphoproteins ( eg. pp38, pSTATs). Expression of these markers was measured by FACS analysis.
Trial information was received from ClinicalTrials.gov and was last updated in May 2014.
Information provided to ClinicalTrials.gov by Stanford University.